Replies to post #101577 on Biotech Values

[DewDiligence]

…the Bernstein analyst is going to look stupid calling for Teva's version to be approved before year end.

Does he care about looking stupid, or does he care about making money for Bernstein clients (and/or the firm itself)? From Bernstein’s behavior in January (#msg-45811783), I suspect the answer is the latter.

p.s. The bogus Bernstein report in January caused MNTA’s share price to reach $16.45 on 1/22/10, which is higher than where it closed today. The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!